Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint ...

Analysts expect Eli Lilly’s EPS to climb 107.9% to $13.14 in fiscal 2024, up from $6.32 in 2023.In fiscal 2025, EPS is projected to increase by 82.9% annually to $24.03.

Good morning, and thank you, Paul, and thanks for joining us for Eli Lilly and Company's Q4 2023 Earnings and 2024 Guidance Call. I'm Joe Fletcher, Senior President of Investor Relations.

In Q4 2024, Eli Lilly's revenue grew 45%, driven by Mounjaro and Zepbound, the company's core weight-loss drugs. Non-incretin revenue grew by 20% compared to Q4 2023. "We exceeded our first-time ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year.

Eli Lilly also posted a 90 bps improvement in gross margin to 83.2% in Q4. Higher revenues clubbed with margin expansion resulted in earnings of $5.32 per share, up over 2x from the $2.49 figure ...

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH.

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion ...

Eli Lilly Mounjaro Zepbound GLP-1 Lilly on Thursday reported fourth-quarter revenue of $13.53 billion, a steep 45% increase over the sum the Indianapolis-based drugmaker generated during the same ...